In the subsequent analysis, associations of CMS with other molecular and clinical features used to classify CRC, e.g., MSI, RAS mutations, BRAF mutations, CpG island methylator phenotype (CIMP), and primary tumor location (left versus right), were evaluated. This evidence concerns the gene BRAF and colorectal carcinoma.